📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-06 14:29
161 analysed today
FollowTelegram
161
Today
149,562
All-time analysed
42,894
Positive
6,654
Negative
91,341
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
12 announcements match the current filters (relevance ≥ 5).
Divi's Labs Q1 FY27: ₹500 Cr Inventory Surge and Progress on 3 Major Capex Projects
Divi's Laboratories reported stable volumes in its generic business for Q1 FY27, though pricing remains competitive due to market conditions. A significant ₹500 crore inventory increase was recorded this quarter, far exceeding the usual ₹50-100 crore run rate, driven by validation projects and higher solvent costs. Three major capex programs are nearing completion and entering the validation phase, which is critical for future commercial supply. The company is also scaling its peptide synthesis capabilities and its nutraceutical portfolio, which now exceeds 100 offerings.
Confidence: HIGH
What changedThis filing provides the detailed transcript of the Q1 FY27 earnings call, clarifying the reasons behind inventory fluctuations and the status of major infrastructure projects.
Why it mattersThe transcript reveals that margin pressure is linked to elevated solvent costs and a strategic inventory buildup for validation batches, which are precursors to commercial revenue from new molecules.
Inventory Change (Q1 FY27): ₹500 crNutraceutical Portfolio: 100+ offeringsCSR Beneficiaries: 1.8 millionTTM Revenue: ₹10560 crOperating Profit Margin (TTM): 32.6%
📅 Short termThe stock may see neutral to cautious sentiment as investors digest the impact of high solvent costs and the large inventory buildup on immediate cash flows.
📈 Long termStructural growth remains tied to the successful ramp-up of the Kakinada plant (Unit 3) and the commercialization of the Custom Synthesis and Peptide pipelines.
⚠ Risk flags
- Elevated solvent costs
- Geopolitical uncertainty in West Asia affecting supply chains
- Revenue concentration in top 5 products
Key Highlights
Inventory change surged to ₹500 crore in Q1 FY27, compared to a typical quarterly run rate of ₹50-100 crore.
Three major capex programs are nearing completion with validation activities currently underway for new products.
The nutraceutical segment has expanded to over 100 offerings across human and animal health over a 20-year period.
CSR initiatives reached more than 1.8 million beneficiaries across Andhra Pradesh and Telangana during 2026.
Unit 3 (Kakinada) is now supporting backward integration and the phased transfer of manufacturing activities.
👀 What to Watch
Monitor the commercialization timeline of the three major capex projects and the stabilization of solvent prices, which management identified as a margin headwind.
Rs 902 Cr Q1 PAT: Divi's Labs Reports 65.5% YoY Profit Growth and Management Appointments
Divi's Laboratories reported a strong start to FY27 with consolidated revenue growing 27.8% YoY to Rs 3,080 Cr. Net profit surged 65.5% YoY to Rs 902 Cr, significantly outpacing revenue growth despite a forex loss of Rs 7 Cr. The Board also elevated two veterans, Mr. B. Vara Prasad and Mr. J. Srinivasa Rao (both with 30+ years at the firm), to Senior Management roles to oversee Engineering and Raw Material procurement. The results reflect robust operational performance with Profit Before Tax (PBT) rising 61% YoY to Rs 1,180 Cr.
Confidence: HIGH
What changedDivi's Labs reported its Q1 FY27 financial results showing substantial profit growth and formalized the promotion of two internal procurement heads to the Senior Management team.
Why it mattersThe significant profit growth indicates strong operational leverage and potentially a higher contribution from the high-margin Custom Synthesis segment. Internal promotions in supply chain management reinforce the company's focus on procurement efficiency and sustainable sourcing.
Consolidated Revenue (Q1 FY27): Rs 3,080 CrConsolidated PAT (Q1 FY27): Rs 902 CrYoY PAT Growth: 65.5%Q1 Revenue vs TTM Revenue: 29.2%Forex Loss: Rs 7 Cr
📅 Short termThe stock is likely to react positively to the strong earnings beat and significant margin expansion compared to the previous year.
📈 Long termLong-term growth is supported by capacity expansion at Kakinada and a strong position in the global CRAMS market, though high P/E (83.3) necessitates sustained high growth.
⚠ Risk flags
- High revenue concentration in top five products
- 90% export dependency makes it sensitive to USFDA regulatory actions
- Forex volatility impacting bottom line
Key Highlights
Consolidated Revenue from operations increased 27.8% YoY to Rs 3,080 Cr for Q1 FY27
Consolidated Net Profit (PAT) grew 65.5% YoY to Rs 902 Cr from Rs 545 Cr in the year-ago period
Profit Before Tax (PBT) reached Rs 1,180 Cr, representing a 61% increase over Q1 FY26
Appointment of two Senior Management Personnel with over 30 and 31 years of internal experience respectively
Forex impact shifted to a loss of Rs 7 Cr compared to a gain of Rs 39 Cr in the previous year's quarter
👀 What to Watch
Investors should monitor the operationalization of the Kakinada plant scheduled for H2 FY25 and its contribution to volume growth. Watch for the company's progress in reducing product concentration risk (currently aiming for <30% for top 5 products) and maintaining OPM above 30%.
65.5% YoY PAT Growth; Divi's Labs Reports Strong Q1 FY27 Revenue of 3,080 Cr
Divi's Laboratories delivered a robust performance for Q1 FY27, with consolidated revenue growing 27.8% YoY to 3,080 Cr. Profit After Tax (PAT) surged 65.5% YoY to 902 Cr, significantly outpacing revenue growth and reflecting strong margin expansion. The company also promoted two internal veterans with over 30 years of experience each to Senior Management roles in procurement and supply chain. Despite a minor forex loss of 7 Cr, the overall operational performance remains highly efficient with PBT margins reaching 37.5%.
Confidence: HIGH
What changedDivi's has shifted from moderate growth to high double-digit growth in both top-line and bottom-line, with significant margin improvement compared to FY26 averages.
Why it mattersThe sharp jump in profitability suggests a strong recovery in the API and Custom Synthesis segments, potentially driven by higher-value projects or improved cost efficiencies in the supply chain.
Consolidated Revenue (Q1 FY27): 3,080 CrConsolidated PAT (Q1 FY27): 902 CrYoY PAT Growth: 65.5%PBT Margin: 37.5%Q1 Revenue vs TTM Revenue: ~29.2%
📅 Short termThe stock is likely to react positively to the significant earnings beat and margin expansion, which exceeds the TTM operating profit margin of 32.6%.
📈 Long termStructural growth remains strong as the company leverages its R&D and new capacity at Kakinada; internal leadership promotions ensure continuity in strategic procurement.
⚠ Risk flags
- High export dependency (90%) makes it sensitive to USFDA regulatory actions
- Revenue concentration in top 5 products
- Forex volatility
Key Highlights
Consolidated Revenue from operations grew 27.8% YoY to 3,080 Cr from 2,410 Cr.
Net Profit (PAT) increased by 65.5% YoY to 902 Cr compared to 545 Cr in the previous year.
Profit Before Tax (PBT) margin expanded significantly to 37.5% from 29.0% in Q1 FY26.
Appointed Mr. B. Vara Prasad and Mr. J. Srinivasa Rao, both with 30+ years at Divi's, to Senior Management.
Reported a forex loss of 7 Cr for the quarter, reversing a 39 Cr gain in the year-ago period.
👀 What to Watch
Investors should monitor the sustainability of these 37%+ PBT margins in upcoming quarters and track the utilization levels of the recently operationalized Kakinada plant. The focus remains on the company's ability to diversify its product concentration away from the top 5 products.
₹30 Dividend: Divi's Labs Sets August 10 for AGM and July 24 as Record Date
Divi's Laboratories has issued the notice for its 36th Annual General Meeting (AGM) scheduled for August 10, 2026. The company has recommended a final dividend of ₹30 per equity share (1,500% of face value) for FY26, which is subject to shareholder approval at the meeting. The record date for determining dividend eligibility is July 24, 2026, with payments expected to begin on August 14, 2026. This follows a year where the company reported a TTM PAT of ₹2,568 Cr.
Confidence: HIGH
What changedThe company has formalized the schedule for its annual shareholder meeting and established the timeline for its FY26 dividend payout.
Why it mattersThis is a routine but significant event for shareholders as it confirms the cash return for the fiscal year and provides a platform for management to discuss the company's strategic progress in CRAMS and API segments.
Dividend per share: ₹30Dividend % of Face Value: 1,500%Record Date: July 24, 2026AGM Date: August 10, 2026Dividend Yield (at current price): 0.41%
📅 Short termThe stock may see minor price adjustments around the ex-dividend date (typically one day before the record date).
📈 Long termLimited structural significance as this is a routine annual administrative and dividend-related filing.
Key Highlights
Final dividend of ₹30 per equity share of face value ₹2 (1,500%) recommended for FY26
Record date for dividend eligibility fixed as Friday, July 24, 2026
36th Annual General Meeting scheduled for August 10, 2026, at 10:00 a.m. IST
Dividend payment to commence from August 14, 2026, post-shareholder approval
Remote e-voting period set from August 06 to August 09, 2026
👀 What to Watch
Investors should ensure their bank details and PAN are updated with their Depository Participant by July 24, 2026, to receive the dividend. Watch for management commentary during the AGM regarding the operationalization of the Kakinada plant.
Divi's Labs FY26 PAT Rises 17% to ₹2,568 Cr; Capitalizes ₹1,544 Cr in Assets
Divi's Laboratories reported a robust performance for FY26, with total income reaching ₹11,067 crores, a 14% increase over the previous year. The company maintained a strong product mix with Custom Synthesis (CS) contributing 55% and Generics 45% of revenue. Despite geopolitical tensions affecting logistics in Q4, Divi's capitalized assets worth ₹1,544 crores during the year, including ₹800 crores in the final quarter, signaling significant capacity expansion. The company also reported an improved material consumption rate of 38.8% and a healthy cash position of ₹3,414 crores.
Key Highlights
FY26 Consolidated Total Income grew to ₹11,067 crores from ₹9,712 crores in FY25.
Custom Synthesis segment contributed 55% of total revenue, reflecting a high-value product mix.
Capitalized assets worth ₹1,544 crores in FY26, with significant focus on Unit 3 and backward integration.
One-time exceptional item of ₹74 crores provided for the implementation of new Labour Codes.
Nutraceuticals business showed strong growth, reaching ₹946 crores compared to ₹781 crores YoY.
👀 What to Watch
Investors should focus on the company's aggressive capitalization and the ramp-up of Unit 3, which are expected to drive future growth. The increasing contribution of Custom Synthesis and the entry into the peptide segment provide high-margin long-term visibility.
Divi's Lab FY26 Revenue Crosses ₹10,000 Cr; Recommends ₹30 Dividend
Divi's Laboratories reported a strong performance for FY26, with annual revenue growing 13% to ₹10,388 crore and PAT increasing 18% to ₹2,607 crore. The company recommended a final dividend of ₹30 per share, reflecting a payout of 1,500% on face value. Despite a one-time exceptional charge of ₹74 crore related to new labour codes, margins remained resilient. Significant capital expenditure is evident with Capital Work-in-Progress doubling to ₹2,113 crore, indicating aggressive future capacity expansion.
Key Highlights
Annual Revenue from operations grew by 13% YoY to ₹10,388 crore in FY26.
Net Profit (PAT) for the full year rose 18% to ₹2,607 crore compared to ₹2,209 crore in FY25.
Board recommended a final dividend of ₹30 per equity share (1,500% of face value) with a record date of July 24, 2026.
Capital Work-in-Progress (CWIP) surged to ₹2,113 crore from ₹1,022 crore, signaling massive capacity expansion.
Net cash inflow from operating activities improved significantly to ₹2,711 crore from ₹1,650 crore in the previous year.
👀 What to Watch
Investors should view the strong revenue growth and the doubling of CWIP as positive indicators for long-term scale-up. The healthy dividend payout and robust cash flow generation reinforce the company's strong fundamental position in the API sector.
Divi's Labs FY26 PAT Rises 18% to ₹2,607 Cr; Recommends ₹30 Final Dividend
Divi's Laboratories reported a robust performance for FY26, with annual revenue from operations growing 13% to ₹10,388 crore compared to ₹9,198 crore in FY25. Net profit for the year increased by 18% to ₹2,607 crore, even after accounting for a one-time exceptional charge of ₹74 crore related to new Labour Codes. The Board has recommended a significant final dividend of ₹30 per share (1,500% of face value), with the record date set for July 24, 2026. The company's balance sheet remains strong with a substantial increase in Capital Work-in-Progress to ₹2,113 crore, signaling aggressive future expansion.
Key Highlights
Annual Revenue from operations increased 13% YoY to ₹10,388 crore in FY26.
Net Profit (PAT) for the full year rose to ₹2,607 crore from ₹2,209 crore in FY25.
Recommended a final dividend of ₹30 per equity share of face value ₹2 each.
Exceptional item of ₹74 crore recognized due to the impact of new Labour Codes on employee benefits.
Capital Work-in-Progress (CWIP) stood at ₹2,113 crore as of March 31, 2026, vs ₹1,022 crore YoY.
👀 What to Watch
The strong earnings growth and high dividend payout reflect healthy operational cash flows and management confidence. Long-term investors should monitor the conversion of the high CWIP into operational revenue as a key growth catalyst.
Divi's Labs FY26 Net Profit Rises 18% to ₹2,607 Cr; Recommends ₹30 Dividend
Divi's Laboratories reported a robust performance for FY26, with annual revenue from operations growing 13% to ₹10,388 crore. Net profit for the full year increased by 18% to ₹2,607 crore, even after accounting for a one-time exceptional expense of ₹74 crore related to new labour codes. The company has recommended a final dividend of ₹30 per share, reflecting a 1,500% payout on face value. A significant highlight is the aggressive capital expenditure, with ₹2,519 crore invested in property, plant, and equipment during the year.
Key Highlights
Annual Revenue from operations increased to ₹10,388 crore in FY26 from ₹9,198 crore in FY25.
Net Profit for the year grew 18% YoY to ₹2,607 crore, with EPS rising to ₹98.19.
Recommended a final dividend of ₹30 per equity share (1,500%) with a record date of July 24, 2026.
Capital expenditure surged to ₹2,519 crore in FY26 compared to ₹1,437 crore in the previous fiscal.
Q4 FY26 standalone revenue stood at ₹2,793 crore with a net profit of ₹756 crore.
👀 What to Watch
The strong earnings growth combined with massive capital expenditure signals management's confidence in future demand and capacity expansion. Long-term investors should maintain their positions as the company continues to demonstrate high operational efficiency and consistent dividend payouts.
Divi's Labs FY26 Net Profit Rises 18% to ₹2,607 Cr; Declares ₹30 Dividend
Divi's Laboratories reported a strong performance for FY26, with annual revenue crossing the ₹10,000 crore milestone to reach ₹10,388 crore. Net profit for the full year grew by 18% to ₹2,607 crore, even after accounting for a one-time exceptional hit of ₹74 crore related to new labour codes. The company demonstrated aggressive expansion plans, with Capital Work-in-Progress doubling to ₹2,113 crore. Additionally, the board recommended a final dividend of ₹30 per share, reflecting healthy cash flow and shareholder returns.
Key Highlights
Annual Revenue from operations grew 13% YoY to ₹10,388 crore in FY26.
Standalone Net Profit for Q4 FY26 stood at ₹756 crore, a 13.3% increase over the previous year's quarter.
Board recommended a final dividend of ₹30 per equity share (1,500%) for the financial year.
Capital Work-in-Progress (CWIP) surged to ₹2,113 crore from ₹1,022 crore, indicating massive capacity expansion.
Reported a one-time exceptional expense of ₹74 crore due to the impact of new Labour Codes.
👀 What to Watch
Investors should focus on the significant doubling of Capital Work-in-Progress, which suggests strong future growth visibility. The stock remains a high-quality play in the API and CRAMS space with consistent dividend payouts.
Divi's Labs Receives ₹570.51 Crore Income Tax Draft Order for FY2022-23
Divi's Laboratories has received a Draft Assessment Order for FY2022-23 (AY 2023-24) from the Income Tax Authority. The order proposes additions and disallowances totaling ₹570.51 crores to the company's returned income. These adjustments are primarily attributed to Transfer Pricing on specified domestic transactions and other corporate tax matters. The company intends to contest the order and file an appeal with the appropriate authorities.
Key Highlights
Draft Order issued under Section 144C(1) of the Income Tax Act for FY2022-23.
Proposed additions and disallowances amount to ₹570.51 crores.
Adjustments involve Transfer Pricing on domestic transactions and corporate tax adjustments.
Penalty proceedings under Section 270A for alleged under-reporting of income to be initiated separately.
Company is evaluating the order and plans to file an appeal within the stipulated time.
👀 What to Watch
Investors should monitor the litigation progress as the proposed amount is significant, though it is currently a draft order and will likely be contested in higher tax forums. No immediate financial impact is expected until the final order is passed and appeals are exhausted.
Divi's Labs Q3FY26: Total Income Up 12% to ₹2,692 Cr; PAT Stable at ₹583 Cr Post-Exceptional Item
Divi's Laboratories reported a 12% year-on-year increase in total income to ₹2,692 crores for Q3FY26, driven by strong performance in Custom Synthesis and Nutraceuticals. While Profit Before Tax (pre-exceptional) grew to ₹854 crores, the bottom line was impacted by a one-time ₹74 crore exceptional charge related to new government labor codes. The company continues to shift its mix toward Custom Synthesis, which now accounts for 57% of revenue. Management confirmed that GLP-1 pilot and commercial blocks are completed and currently undergoing validation.
Key Highlights
Total income for Q3FY26 rose to ₹2,692 crores from ₹2,401 crores in the previous year.
Custom Synthesis segment contributed 57% of revenue, while Generics accounted for 43%.
Material consumption costs improved to 36.3% of sales, down from 39.8% in Q3FY25.
Exceptional item of ₹74 crores recognized due to revised employee benefit obligations under new labor codes.
Capital work in progress (CWIP) remains high at ₹2,394 crores, focusing on GLP-1 capacity and Unit 3 expansions.
👀 What to Watch
Investors should focus on the improving gross margins and the progress in the high-growth GLP-1/Peptide segment which is nearing commercialization. The one-time exceptional hit is non-recurring, and the underlying operational strength remains robust with a successful US FDA inspection at Unit 1.
Divi's Labs Q3 FY26 Consolidated Revenue up 12% YoY to ₹2,604 Cr; PAT Flat at ₹583 Cr
Divi's Laboratories reported a 12.3% YoY growth in consolidated revenue at ₹2,604 crore for Q3 FY26. However, consolidated net profit remained nearly flat at ₹583 crore, compared to ₹589 crore in the previous year, primarily due to a one-time exceptional charge of ₹74 crore related to new Labour Codes. On a sequential basis, revenue and PAT declined by 4.1% and 15.4% respectively. Despite the flat PAT, the 9-month consolidated profit shows a healthy 18.8% growth YoY reaching ₹1,817 crore.
Key Highlights
Consolidated Revenue from operations grew 12.3% YoY to ₹2,604 crore.
Consolidated Net Profit stood at ₹583 crore, down 1% YoY, impacted by a ₹74 crore exceptional item.
Profit Before Tax (before exceptional items) increased 17.6% YoY to ₹854 crore.
Nine-month (9M FY26) consolidated PAT grew 18.8% YoY to ₹1,817 crore.
Forex gain for the quarter was significantly lower at ₹18 crore compared to ₹64 crore in the previous quarter.
👀 What to Watch
Investors should look past the one-time exceptional labour code impact and focus on the steady 12% top-line growth. While sequential performance was soft, the 9-month growth trajectory remains positive for long-term holders.
